Alzheimer’s disease is best described as a progressive neurodegenerative disorder that gradually destroys memory, thinking, and the ability to carry out daily activities. It accounts for at least two-thirds of all dementia cases in people aged 65 and older, making it by far the most common cause of dementia. The disease has a slow, insidious onset and worsens over time as brain cells die in a spreading pattern that eventually affects nearly every region of the brain.
Understanding what makes Alzheimer’s distinct from normal aging or other forms of dementia matters, whether you’re studying for an exam, researching a loved one’s diagnosis, or simply trying to make sense of a condition that affects roughly 49 million adults worldwide.
What Happens Inside the Brain
Two abnormal protein buildups define Alzheimer’s at the biological level. The first is a sticky protein fragment called amyloid-beta, which clumps together into plaques outside brain cells. The second is a protein called tau, which becomes chemically altered and twists into tangles inside brain cells. These two hallmarks, plaques and tangles, are what distinguish Alzheimer’s from other types of dementia when brain tissue is examined.
The damage starts at the connections between brain cells, called synapses. Soluble clusters of amyloid-beta gather at these junctions and trigger a cascade of dysfunction: they disrupt signaling, throw off calcium balance inside cells, and activate enzymes that break down the structural supports of neural connections. Altered tau then amplifies the damage by further destabilizing those same connections and interfering with energy delivery to synapses. Synapse loss actually begins before plaques and tangles are fully formed, and it correlates more closely with cognitive decline than plaque count alone. This is why someone can have significant plaque buildup on a brain scan but still function relatively well, while another person with less visible pathology may already be struggling.
Over time, neurons die in expanding waves. The brain physically shrinks, sometimes losing substantial volume by the disease’s final stages.
How Symptoms Progress Through Three Stages
Alzheimer’s is typically divided into mild, moderate, and severe stages, though the boundaries between them are gradual rather than sharp.
In the mild stage, the most noticeable problems involve memory and everyday planning. People get lost in familiar places, repeat questions, struggle with bills or finances, and take longer to complete routine tasks. Personality shifts may appear, subtle at first. This is the stage where most people receive their diagnosis.
The moderate stage is usually the longest. Damage spreads to brain areas controlling language, reasoning, and sensory processing. People begin having trouble recognizing family and friends, can no longer manage multistep tasks like getting dressed, and struggle to adapt to new situations. Hallucinations, delusions, paranoia, and impulsive behavior can emerge. This stage often places the heaviest burden on caregivers.
In severe Alzheimer’s, plaques and tangles have spread throughout the brain. Communication becomes impossible. The person is completely dependent on others, often bedbound as the body’s basic functions decline. Average survival after diagnosis ranges from three to 11 years, with pneumonia, infections, dehydration, and falls being the most common causes of death.
Beyond Memory Loss: Behavioral Symptoms
Alzheimer’s is often thought of purely as a memory disease, but behavioral and psychological symptoms are nearly universal. Up to 97% of people with dementia experience them at some point. Depression and apathy are the most common, while delusions, agitation, and repetitive behaviors like pacing or fidgeting each affect about a third of patients.
Delusions often carry paranoid themes. A person may become convinced that a spouse is an impostor or that someone is stealing from them. Sleep disturbances are also frequent, and many people experience “sundowning,” a pattern of increased confusion, agitation, and restlessness in the late afternoon and evening that affects up to two-thirds of patients. Appetite changes, anxiety, irritability, and disinhibition round out a symptom profile that can be more distressing for families than the cognitive decline itself.
Risk Factors and Genetics
Age is the strongest risk factor. Most cases develop after age 65, though early-onset Alzheimer’s can appear as early as the mid-30s. A gene called APOE4 plays a significant role: people who inherit two copies (one from each parent) have roughly a 60% chance of developing Alzheimer’s dementia by age 85. In autopsy studies, nearly all people with two copies showed Alzheimer’s brain pathology from age 55 onward, compared with about half of those without the gene variant.
Carrying one copy of APOE4 raises risk to a lesser degree. But APOE4 is a risk factor, not a guarantee. Many carriers never develop symptoms, and many people with Alzheimer’s don’t carry the gene at all. Other contributing factors include cardiovascular health, diabetes, head injuries, physical inactivity, social isolation, and lower levels of education, though the relative weight of each varies from person to person.
How Alzheimer’s Differs From Other Dementias
Dementia is a broad term for significant cognitive decline that interferes with daily life. Alzheimer’s is one specific cause, and several features set it apart. The onset is gradual and almost imperceptible at first, with short-term memory loss as the earliest and most prominent symptom. Vascular dementia, the second most common type, can begin more abruptly (often after a stroke) and tends to affect judgment and planning before memory. Its symptom pattern is less predictable, depending on which blood vessels in the brain are affected.
Other dementias have their own signatures. Lewy body dementia often starts with visual hallucinations and fluctuating alertness. Frontotemporal dementia typically strikes younger (often before age 65) and begins with personality changes or language problems rather than memory loss. Alzheimer’s distinctive combination of slow onset, early memory impairment, and the specific plaque-and-tangle pathology is what makes it a separate diagnosis.
How It’s Diagnosed Today
Diagnosis has shifted substantially in recent years. Revised criteria now allow doctors to confirm Alzheimer’s using biomarkers rather than relying solely on symptoms and ruling out other conditions. A single abnormal result on what researchers call a “Core 1” biomarker test, which detects amyloid plaques or Alzheimer’s-related tau, is now considered sufficient to establish a diagnosis at any point in the disease. These tests include PET brain scans, spinal fluid analysis, and increasingly, blood tests that measure a specific form of phosphorylated tau. The blood tests are making early detection far more accessible than it was even five years ago.
Current Treatment Options
For decades, Alzheimer’s treatments could only manage symptoms without affecting the underlying disease. That changed with the approval of new antibody-based drugs that target amyloid-beta plaques directly. Lecanemab slowed cognitive decline by about 27% in clinical trials, and donanemab slowed it by roughly 33% in participants with lower levels of tau buildup. These are modest but real effects, and they represent the first treatments that alter the biological course of the disease rather than just easing symptoms.
These drugs work best in early stages, before extensive brain damage has occurred, which is one reason early diagnosis has become such a priority. They also carry risks, including brain swelling and small brain bleeds, that require careful monitoring. Older medications that boost chemical signaling between surviving neurons remain in use to help with day-to-day function, but they do not slow progression.